Whitney Walker
Family · Ripley, MSNPI 1245638642
Payments from drug & device makers
Across 156 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$293
- GSK$276
- Boston Scientific$263
- Amgen$259
- AstraZeneca$222
- Novo Nordisk$220
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 22 | $293 |
| GSK | 17 | $276 |
| Boston Scientific | 5 | $263 |
| Amgen(2 entities) | 17 | $259 |
| AstraZeneca | 9 | $222 |
| Novo Nordisk | 16 | $220 |
| Lilly USA, LLC | 10 | $160 |
| Abbott | 8 | $149 |
| AbbVie | 7 | $126 |
| Pfizer | 6 | $121 |
| Bayer | 6 | $114 |
| Johnson & Johnson | 6 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| Amarin Pharma, Inc. | 3 | $59 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| IBSA Pharma Inc. | 2 | $32 |
| Novartis | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Medtronic | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$110
How this compares
$2,733 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 206 | $283,372 |
| EliquisApixaban | 152 | $249,004 |
| FarxigaDapagliflozin Propanediol | 146 | $217,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $167,127 |
| JardianceEmpagliflozin | 111 | $164,229 |
| XareltoRivaroxaban | 108 | $140,637 |
| TrulicityDulaglutide | 77 | $108,749 |
| JanuviaSitagliptin Phosphate | 68 | $93,723 |
| MounjaroTirzepatide | 68 | $86,303 |
| EntrestoSacubitril/Valsartan | 47 | $61,869 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $59,413 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $54,862 |
| LinzessLinaclotide | 41 | $54,497 |
| TradjentaLinagliptin | 37 | $54,130 |
| Xigduo XrDapaglifloz Propaned/Metformin | 30 | $41,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $220 | $325,834232 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $293 | $273,221179 claims |
| PfizerEliquis, Dilantin | $121 | $251,895165 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $222 | $250,836175 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $160 | $195,052145 claims |
| GSKTrelegy Ellipta | $276 | $167,127113 claims |
| Johnson & JohnsonXarelto | $95 | $140,637108 claims |
| NovartisEntresto | $27 | $61,86947 claims |
| AbbVieLinzess | $126 | $54,49741 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $16,92417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Ripley
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.